Araştırma Makalesi
BibTex RIS Kaynak Göster

Kararsız angina pektoris, ST elevasyonlu miyokard enfarktüsü (STEMI) ve Non-STEMI olan hastalarda omentin düzeylerinin değerlendirilmesi

Yıl 2020, , 1137 - 1142, 01.12.2020
https://doi.org/10.28982/josam.804767

Öz

Amaç: Çalışma vaka-kontrol şeklinde dizayn edildi. Akut koroner sendrom (AKS), uzun süreli iskemi sonrası miyokard nekrozu ile sonuçlanabilen iskemik bir kalp hastalığıdır. Omentin (intelectin-1), yağ dokusundan salınan yeni bir biyobelirteçtir. Omentin koroner arter hastalığı (CAD) ile ilişkilidir ve akut iskemik hasarı azaltıcı etkiye sahiptir. Bu çalışma, kararsız anjina pektoris (USAP), ST elevasyonsuz miyokard enfarktüsü (NSTEMI) ve ST elevasyonlu miyokard enfarktüsü (STEMI) olan hastalarda omentin düzeylerini değerlendirmeyi amaçlamıştır.
Yöntemler: Bu çalışmaya prospektif olarak 59 AKS hastası ve 22 sağlıklı birey dahil edildi. Semptomların başlamasından sonraki altı saat içinde her hastadan alınan venöz kandan kreatin kinaz MB formu (CKMB), troponin, miyoglobin ve omentin düzeyleri ölçüldü. Plazma omentin seviyeleri, bir omentin enzimine bağlı immünosorban test kiti ile belirlenmiştir.
Bulgular: Hasta grubu kontrol grubundan daha yaşlıydı (P<0,05) ancak cinsiyet açısından gruplar arasında fark yoktu (P>0,05). Hasta grubunda sigara içme oranı daha fazlaydı ve hasta grubu kontrol grubuna göre daha ağırdı (P>0,05). AKS hastalarında ve kontrol grubunda omentin düzeyleri benzerdi (6,0 (1,7) ve 6,3 (1,3); P=0,40). CKMB, troponin, miyoglobin ve omentin düzeyleri arasında anlamlı bir ilişki yoktu. CKMB, troponin, miyoglobin ve omentin düzeyleri arasında anlamlı bir korelasyon yoktu, ayrıca AKS alt gruplarında omentin düzeyleri benzerdi (P=0,58). Vücut kitle indeksi ile omentin düzeyleri arasında anlamlı bir ilişki yoktu (r = -0,186, P=0,09).
Sonuç: Bu çalışma AKS hastalarında omentin ve miyoglobin düzeyleri arasında anlamlı bir ilişki olmadığını ortaya koymuştur. Omentin düzeylerinin kan konsantrasyonlarının AKS ile ilişkisinin anlaşılmasındaki potansiyel faydası daha fazla çalışmaya ihtiyaç duyar.

Kaynakça

  • 1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.
  • 2. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Journal of the American College of Cardiology. 2007;50(22):2173–95.
  • 3. Anwaruddin S, Januzzi Jr JL, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. American journal of clinical pathology. 2005;123(1):140–5.
  • 4. Koleva DI, Orbetzova MM, Atanassova PK. Adipose Tissue Hormones and Appetite and Body Weight Regulators an Insulin Resistance/ Folia medica. 2013;55(1):25–32.
  • 5. Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression. 2005;1732(1–3):96–102.
  • 6. Sengul E, Duygulu G, Dindar S, Bunul F. Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease. Renal failure. 2013;35(8):1089–93.
  • 7. Tan Y-L, Zheng X-L, Tang C-K. The protective functions of omentin in cardiovascular diseases. Clinica Chimica Acta. 2015;448:98–106.
  • 8. Jaikanth C, Gurumurthy P, Cherian K, Indhumathi T. Emergence of omentin as a pleiotropic adipocytokine. Experimental and Clinical Endocrinology & Diabetes. 2013;121(07):377–83.
  • 9. Duan X-Y, Xie P-L, Ma Y-L, Tang S-Y. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino acids. 2011;41(5):1223–31.
  • 10. Van de Voorde J, Pauwels B, Boydens C, Decaluwé K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62(11):1513–21.
  • 11. Shang F-J, Wang J-P, Liu X-T, Zheng Q-S, Xue Y-S, Wang B, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers. 2011;16(8):657–62.
  • 12. Zhong X, Zhang H, Tan H, Zhou Y, Liu F, Chen F, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacologica Sinica. 2011;32(7):873–8.
  • 13. Kadoglou NP, Tahmatzidis DK, Giannakoulas C, Kapelouzou A, Gkontopoulos A, Parissis J, et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: KOZANI STUDY. Journal of Cardiovascular Medicine. 2015;16(5):341–6.
  • 14. Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase-and Akt-dependent mechanisms. Journal of the American College of Cardiology. 2014;63(24):2722–33.
  • 15. Türkcü FM, Şahin A, Cingü AK, Kaya S, Yüksel H, Cinar Y, et al. Serum omentin, resistin and tumour necrosis factor-α levels in Behcet patients with and without ocular involvement. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2015;253(9):1565–8.
  • 16. Narumi T, Watanabe T, Kadowaki S, Kinoshita D, Yokoyama M, Honda Y, et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovascular diabetology. 2014;13(1):84.
  • 17. Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetology & metabolic syndrome. 2012;4(1):37.
  • 18. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochemical and biophysical research communications. 2011;408(2):339–43.
  • 19. Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. Journal of Biological Chemistry. 2012;287(1):408–17.
  • 20. De Jager SC, Pasterkamp G. Atheroprotective properties of human Omentin-1 in experimental atherosclerosis. 2016;???:???.
  • 21. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, et al. Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovascular diabetology. 2011;10(1):87.
  • 22. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nature Reviews Endocrinology. 2015;11(6):363.
  • 23. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochemical and biophysical research communications. 2010;393(4):668–72.
  • 24. Moreno‐Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández‐Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity. 2011;19(8):1552–9.
  • 25. Du Y, Ji Q, Cai L, Huang F, Lai Y, Liu Y, et al. Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis. Cardiovascular diabetology. 2016;15(1):90.
  • 26. Watanabe K, Watanabe R, Konii H, Shirai R, Sato K, Matsuyama T, et al. Counteractive effects of omentin-1 against atherogenesis. Cardiovascular research. 2016;110(1):118–28.
  • 27. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219(2):811–4.
  • 28. Uemura Y, Shibata R, Kanemura N, Ohashi K, Kambara T, Hiramatsu-Ito M, et al. Adipose-derived protein omentin prevents neointimal formation after arterial injury. The FASEB Journal. 2015;29(1):141–51.
  • 29. Zhu Y, Hu C, Du Y, Zhang J, Liu J, Cheng G, et al. Time-Dependent Change in Omentin-1 Level Correlated with Early Improvement of Myocardial Function in Patients with First Anterior ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention. Journal of atherosclerosis and thrombosis. 2019;26(10):856–67.
  • 30. Harada K, Shibata R, Ouchi N, Tokuda Y, Funakubo H, Suzuki M, et al. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis. 2016;251:299–304.
  • 31. Wu S-S, Liang Q-H, Liu Y, Cui R-R, Yuan L-Q, Liao E-Y. Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. International journal of endocrinology. 2013;2013.

Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI

Yıl 2020, , 1137 - 1142, 01.12.2020
https://doi.org/10.28982/josam.804767

Öz

Aim: Acute coronary syndrome (ACS) is an ischemic cardiac disease that could result in myocardial necrosis with prolonged ischemia. Omentin (intelectin-1) is a new biomarker that is released from adipose tissue. It is associated with coronary artery disease (CAD) and has an acute ischemic injury-reducing effect. This study aimed to assess the omentin levels in patients with unstable angina pectoris (USAP), Non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevated myocardial infarction (STEMI).
Methods: This case-control prospective study included 59 patients with ACS and 22 healthy subjects. MB fraction of creatine kinase (CKMB), troponin, myoglobin, and omentin levels were measured from venous blood obtained from each patient within six hours after the onset of symptoms. Plasma omentin levels were determined with an omentin enzyme-linked immunosorbent assay kit.
Results: The patient group was older than the control group (P<0.05) but there was no difference between the groups in terms of gender (P>0.05). The rate of smoking was higher in the patient group, and the patient group was heavier than the control group (P>0.05). Omentin levels were similar in ACS patients and control subjects (6.0 (1.7) vs. 6.3 (1.3), P=0.40). There was no significant correlation among CKMB, troponin, myoglobin, and omentin levels. Moreover, omentin levels were similar in ACS subgroups (P=0.58). There was no significant correlation between body mass index and omentin levels (r =-0.186, P=0.09).
Conclusion: This study revealed that there was no significant relationship between omentin and myoglobin levels in ACS patients. The potential usefulness of blood concentrations of omentin levels in understanding the relationship with ACS warrants further studies.

Kaynakça

  • 1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–209.
  • 2. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Journal of the American College of Cardiology. 2007;50(22):2173–95.
  • 3. Anwaruddin S, Januzzi Jr JL, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. American journal of clinical pathology. 2005;123(1):140–5.
  • 4. Koleva DI, Orbetzova MM, Atanassova PK. Adipose Tissue Hormones and Appetite and Body Weight Regulators an Insulin Resistance/ Folia medica. 2013;55(1):25–32.
  • 5. Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression. 2005;1732(1–3):96–102.
  • 6. Sengul E, Duygulu G, Dindar S, Bunul F. Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease. Renal failure. 2013;35(8):1089–93.
  • 7. Tan Y-L, Zheng X-L, Tang C-K. The protective functions of omentin in cardiovascular diseases. Clinica Chimica Acta. 2015;448:98–106.
  • 8. Jaikanth C, Gurumurthy P, Cherian K, Indhumathi T. Emergence of omentin as a pleiotropic adipocytokine. Experimental and Clinical Endocrinology & Diabetes. 2013;121(07):377–83.
  • 9. Duan X-Y, Xie P-L, Ma Y-L, Tang S-Y. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino acids. 2011;41(5):1223–31.
  • 10. Van de Voorde J, Pauwels B, Boydens C, Decaluwé K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62(11):1513–21.
  • 11. Shang F-J, Wang J-P, Liu X-T, Zheng Q-S, Xue Y-S, Wang B, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers. 2011;16(8):657–62.
  • 12. Zhong X, Zhang H, Tan H, Zhou Y, Liu F, Chen F, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacologica Sinica. 2011;32(7):873–8.
  • 13. Kadoglou NP, Tahmatzidis DK, Giannakoulas C, Kapelouzou A, Gkontopoulos A, Parissis J, et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: KOZANI STUDY. Journal of Cardiovascular Medicine. 2015;16(5):341–6.
  • 14. Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase-and Akt-dependent mechanisms. Journal of the American College of Cardiology. 2014;63(24):2722–33.
  • 15. Türkcü FM, Şahin A, Cingü AK, Kaya S, Yüksel H, Cinar Y, et al. Serum omentin, resistin and tumour necrosis factor-α levels in Behcet patients with and without ocular involvement. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2015;253(9):1565–8.
  • 16. Narumi T, Watanabe T, Kadowaki S, Kinoshita D, Yokoyama M, Honda Y, et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovascular diabetology. 2014;13(1):84.
  • 17. Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetology & metabolic syndrome. 2012;4(1):37.
  • 18. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochemical and biophysical research communications. 2011;408(2):339–43.
  • 19. Maruyama S, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. Journal of Biological Chemistry. 2012;287(1):408–17.
  • 20. De Jager SC, Pasterkamp G. Atheroprotective properties of human Omentin-1 in experimental atherosclerosis. 2016;???:???.
  • 21. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, et al. Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovascular diabetology. 2011;10(1):87.
  • 22. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nature Reviews Endocrinology. 2015;11(6):363.
  • 23. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochemical and biophysical research communications. 2010;393(4):668–72.
  • 24. Moreno‐Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández‐Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity. 2011;19(8):1552–9.
  • 25. Du Y, Ji Q, Cai L, Huang F, Lai Y, Liu Y, et al. Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis. Cardiovascular diabetology. 2016;15(1):90.
  • 26. Watanabe K, Watanabe R, Konii H, Shirai R, Sato K, Matsuyama T, et al. Counteractive effects of omentin-1 against atherogenesis. Cardiovascular research. 2016;110(1):118–28.
  • 27. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219(2):811–4.
  • 28. Uemura Y, Shibata R, Kanemura N, Ohashi K, Kambara T, Hiramatsu-Ito M, et al. Adipose-derived protein omentin prevents neointimal formation after arterial injury. The FASEB Journal. 2015;29(1):141–51.
  • 29. Zhu Y, Hu C, Du Y, Zhang J, Liu J, Cheng G, et al. Time-Dependent Change in Omentin-1 Level Correlated with Early Improvement of Myocardial Function in Patients with First Anterior ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention. Journal of atherosclerosis and thrombosis. 2019;26(10):856–67.
  • 30. Harada K, Shibata R, Ouchi N, Tokuda Y, Funakubo H, Suzuki M, et al. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis. 2016;251:299–304.
  • 31. Wu S-S, Liang Q-H, Liu Y, Cui R-R, Yuan L-Q, Liao E-Y. Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. International journal of endocrinology. 2013;2013.
Toplam 31 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Kalp ve Damar Cerrahisi
Bölüm Araştırma makalesi
Yazarlar

Tayyar Akbulut 0000-0002-5890-8420

Ramazan Asoğlu 0000-0002-4777-1166

Mahmut Özdemir 0000-0002-0021-3415

Nesim Aladağ 0000-0003-2346-1152

İrem Karauzum 0000-0002-8015-6253

Abdulcebbar Şipal Bu kişi benim 0000-0002-6379-8342

Kurtuluş Karaüzüm 0000-0002-7088-1590

Yayımlanma Tarihi 1 Aralık 2020
Yayımlandığı Sayı Yıl 2020

Kaynak Göster

APA Akbulut, T., Asoğlu, R., Özdemir, M., Aladağ, N., vd. (2020). Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI. Journal of Surgery and Medicine, 4(12), 1137-1142. https://doi.org/10.28982/josam.804767
AMA Akbulut T, Asoğlu R, Özdemir M, Aladağ N, Karauzum İ, Şipal A, Karaüzüm K. Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI. J Surg Med. Aralık 2020;4(12):1137-1142. doi:10.28982/josam.804767
Chicago Akbulut, Tayyar, Ramazan Asoğlu, Mahmut Özdemir, Nesim Aladağ, İrem Karauzum, Abdulcebbar Şipal, ve Kurtuluş Karaüzüm. “Evaluation of Omentin Levels in Patients With Unstable Angina Pectoris, Non-ST Elevated Myocardial Infarction (NSTEMI) and STEMI”. Journal of Surgery and Medicine 4, sy. 12 (Aralık 2020): 1137-42. https://doi.org/10.28982/josam.804767.
EndNote Akbulut T, Asoğlu R, Özdemir M, Aladağ N, Karauzum İ, Şipal A, Karaüzüm K (01 Aralık 2020) Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI. Journal of Surgery and Medicine 4 12 1137–1142.
IEEE T. Akbulut, R. Asoğlu, M. Özdemir, N. Aladağ, İ. Karauzum, A. Şipal, ve K. Karaüzüm, “Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI”, J Surg Med, c. 4, sy. 12, ss. 1137–1142, 2020, doi: 10.28982/josam.804767.
ISNAD Akbulut, Tayyar vd. “Evaluation of Omentin Levels in Patients With Unstable Angina Pectoris, Non-ST Elevated Myocardial Infarction (NSTEMI) and STEMI”. Journal of Surgery and Medicine 4/12 (Aralık 2020), 1137-1142. https://doi.org/10.28982/josam.804767.
JAMA Akbulut T, Asoğlu R, Özdemir M, Aladağ N, Karauzum İ, Şipal A, Karaüzüm K. Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI. J Surg Med. 2020;4:1137–1142.
MLA Akbulut, Tayyar vd. “Evaluation of Omentin Levels in Patients With Unstable Angina Pectoris, Non-ST Elevated Myocardial Infarction (NSTEMI) and STEMI”. Journal of Surgery and Medicine, c. 4, sy. 12, 2020, ss. 1137-42, doi:10.28982/josam.804767.
Vancouver Akbulut T, Asoğlu R, Özdemir M, Aladağ N, Karauzum İ, Şipal A, Karaüzüm K. Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI. J Surg Med. 2020;4(12):1137-42.